Target intelligence / Profile preview

5-hydroxytryptamine receptor 3A (5-HT3A) (5-HT3A)

Target
5-HT3A
Molecular classification
Ion channel, Ligand-gated ion channel, Receptor, Cys-loop receptor family
01

Overview

The 5-hydroxytryptamine receptor 3A (5-HT3A) is a member of the Cys-loop family of ligand-gated ion channels and represents the only ionotropic serotonin receptor (UniProt: P46098). Unlike other serotonin receptors that are G protein-coupled, the 5-HT3A receptor functions as a non-selective cation channel that mediates fast excitatory neurotransmission in both the central and peripheral nervous systems (PubMed: 25160501). It is primarily located on terminals of the vagus nerve and within the area postrema of the brainstem, where it plays a critical role in the integration of the emetic reflex (StatPearls: NBK554413). In the gastrointestinal tract, these receptors regulate visceral perception and intestinal motility, making them significant targets for treating irritable bowel syndrome (PubMed: 17350074). Pharmacological modulation typically involves the use of "setron" class antagonists, which are gold-standard treatments for chemotherapy-induced and postoperative nausea and vomiting (PubChem: CID 5284564). Beyond emesis, the receptor is implicated in psychiatric conditions such as anxiety and schizophrenia, though therapeutic applications in these areas remain a subject of ongoing research (NIH: PMC3071730). Safety considerations for 5-HT3A antagonists include potential cardiovascular effects like QT prolongation and gastrointestinal issues such as severe constipation (FDA: Drug Safety Communication 2012).

Other names
HTR3ASerotonin receptor 3A5-hydroxytryptamine receptor 3 subunit A5-HT3R
02

Mechanism of action

Competitive antagonism of the 5-HT3 receptor, which inhibits the opening of the non-selective cation channel, thereby preventing serotonin-mediated depolarization of vagal afferents and central neurons (StatPearls: NBK554413).

03

Biological functions

Signal transductionFast excitatory neurotransmissionIon transportDepolarization of post-synaptic membranes
04

Disease associations

Chemotherapy-induced nausea and vomitingPostoperative nausea and vomitingIrritable bowel syndromeAnxietySchizophrenia
05

Safety considerations

QT interval prolongationConstipationHeadacheSerotonin syndromeIschemic colitis
06

Interacting drugs

Ondansetron

8 more in the full profile.

07

Biomarkers

HTR3A gene polymorphisms (e.g., rs1062613)HTR3B gene variants (e.g., rs1176744)

Beyond the preview

Go deeper on 5-hydroxytryptamine receptor 3A (5-HT3A) (5-HT3A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-hydroxytryptamine receptor 3A (5-HT3A) (5-HT3A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call